Status:
UNKNOWN
Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer
Lead Sponsor:
University of Tennessee
Collaborating Sponsors:
CellSight Technologies, Inc.
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
21+ years
Phase:
PHASE1
Brief Summary
This study is to assess the biodistribution and kinetics of a novel T-cell imaging agent in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy. Th...
Detailed Description
The overall goal of this project is to evaluate the ability of \[18F\]-AraG, a novel T-cell activation imaging biomarker, to measure T-cell activation before and after treatment with programmed death ...
Eligibility Criteria
Inclusion
- This study is open to all adult subjects with histological confirmation of NSCLC enrolled in the parent protocol.
- Age 21 years of age or greater
- ECOG performance status of 0, 1, 2 or 3 at the time of enrollment.
- Patient with life expectancy ≥ 24 weeks from the time of screening to the study
- Ability to give informed consent
Exclusion
- Patients with severe claustrophobia (patients with milder forms of claustrophobia that can be successfully allayed with oral anxiolytic therapy are allowed).
- Severe impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73 m2 and/or on dialysis.
- Pregnancy
- Breast Feeding an infant
- Unable to tolerate the expected radiation therapy prescription
Key Trial Info
Start Date :
July 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04052412
Start Date
July 16 2019
End Date
December 31 2023
Last Update
May 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tennessee Medical Center
Knoxville, Tennessee, United States, 37920